A Non-randomized Open-label Multi-center Phase I/II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed/Refractory Solid Tumors or Lymphoma
James Croop, MD, PhD
Primary Investigator
Brief description of study
This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.
Detailed description of study
This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: lymphoma,solid tumor,riley
-
Age: Between 1 Years - 21 Years
-
Gender: All
Inclusion Criteria
Confirmation of diagnosis:
Phase I: Patients must have histologic verification of a solid tumor or lymphoma malignancy at diagnosis for which there is no standard curative anti-cancer treatment or treatment is no longer effective and must have received greater than or equal to 1 prior line of therapy.
Phase II: patients must have histologically verified tumor at initial diagnosis and radiologically or histologically confirmed status at inclusion as indicated in the following: neuroblastoma, osteosarcoma, rhabdomyosarcoma or Ewing sarcoma.
Patients with solid tumors must have measurable or evaluable (for neuroblastoma and Ewing sarcoma) disease.
Adequate bone marrow, renal and liver function.
Exclusion Criteria
Active or uncontrolled infection
History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)
Diabetes mellitus
Uncontrolled arterial hypertension despite optimal medical management (per institutional guidelines)
Patients with central nervous system (CNS) malignancies
Additional Information:
Participants will not be paid for their participation.
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
